Omega-3 polyunsaturated fatty acids
Omega-3 polyunsaturated fatty acids has been studied in 74 papers since 2012: 11 trials and 14 observational studies in people, 5 in animals, 42 reviews; 20 in the past year. The newest paper, Nov 12, 2026: “Marine Products and Age-Related Diseases: The Path from Pre-Clinical Research to Regulatory Approval for thpe Treatment of Neurodegenerative and Musculoskeletal Diseases”.
74 papers study it88 findingsUpdated
Research on it is growing 68% faster than aging research as a whole: 12 papers in the latest year counted
3 new papers in 30 daysSee all 74 papers on omega-3 polyunsaturated fatty acids
At a glance
Omega-3 polyunsaturated fatty acids are linked with less unhealthy aging in a human cohort; a trial shows no clear slowing of cognitive decline in older adults with memory complaints. One group reports the human results. Papers report company ties; most registered trials across uses have developer sponsors, and some ended over a year ago without posted results.
88 findings in 46 papers from 2012 to 2026, 6 of them since April 2026
The findings reach people, from one lab or study. 29 independent labs in 19 countries; 21 trials, 10 about aging, 3 with no results posted.
“The multidomain intervention and polyunsaturated fatty acids, either alone or in combination, had no significant effects on cognitive decline over 3 years in elderly people with memory complaints”
3 of its findings point the other way.
- 29 independent labs in 19 countries
- 3 findings against
- 21 trials, 10 about aging, 3 with no results posted
- Funders: National Institutes of Health and others
- 5 of 60 findings with company ties
- 14 of 21 trials sponsored by its developers
- Human trial11
- Humans14
- Animals5
Studies in people
See all 10 studies of omega-3 polyunsaturated fatty acids in people10 studies gave omega-3 polyunsaturated fatty acids to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on functional recovery no change: Has no effect on creatine kinase and inflammatory markers | Randomized trial8 weeks | 43 peopleBoth65–85 yearsOlder adults; after eccentric-emphasized leg extensions | Age and ageing, Oct 31, 2026 |
down: Decreases brain entropy | Randomized trial52-week | 20 peopleolder adultsOlder adults; Patient cohorts | Journal of affective disorders, Jan 26, 2024 |
up: Increases erythrocyte membrane EPA and DHA content down: Decreases inflammation mediators down: Decreases cardiac damage markers | Randomized trialthree weeks | 24 peopleMen3 weeks of supplementation compared with baseline | Journal of human kinetics, Oct 27, 2023 |
down: Decreases exercise responsiveness | Randomized trial6 months | 65 people29 male/34 female71.4 ± 4.6 yearsIndependently living adults without a known chronic debilitating disease | Nutrients, Aug 27, 2022 |
no change: Has no effect on appendicular lean mass down: Impairs isometric knee flexion peak torqued = −0.43 down: Decreases triacylglycerols | Randomized trial24-wk | 107 peopleBoth≥65 y of ageUrban community-dwelling men and women | The American journal of clinical nutrition, Apr 20, 2021 |
What did studies of omega-3 polyunsaturated fatty acids find?
63Studies of omega-3 polyunsaturated fatty acids measured 63 outcomes; the most studied are inflammation (3 studies), muscle strength (2) and muscle protein synthesis (2).
Inflammation
downin reviews2downin humans1
3 studies
Inflammation
downin reviews2downin humans1
Omega-3 polyunsaturated fatty acids decrease inflammation.
Review
Omega-3 polyunsaturated fatty acids decrease inflammation in humans.
Review
Omega-3 polyunsaturated fatty acids inhibit inflammation.
Reviewmuscle
Muscle strength
upin humans2
2 studies
Muscle strength
upin humans2
Omega-3 polyunsaturated fatty acids improve muscle strength in humans.
Human trial6 monthsn = 65
Omega-3 polyunsaturated fatty acids improve muscle strength in humans (healthy older adults) (3.1 ± 14.7% increase in placebo vs. 7.5 ± 14.1% increase in n3-PUFA; p = 0.039).
Human trialhealthy older adults4 g/day6 monthsn = 30
Omega-3 polyunsaturated fatty acids increase muscle strength in humans (combined with resistance exercise training).
Reviewcombined with resistance exercise trainingwomens
muscle protein synthesis
upin humans1upin reviews1
2 studies
muscle protein synthesis
upin humans1upin reviews1
Omega-3 polyunsaturated fatty acids increase muscle protein synthesis (via the mTOR pathway).
Reviewvia the mTOR pathwaymuscle
Omega-3 polyunsaturated fatty acids increase muscle protein synthesis in humans (sedentary).
Reviewsedentaryfish oil-derivedskeletal muscle
Muscle function
upin humans2
2 studies
Muscle function
upin humans2
Omega-3 polyunsaturated fatty acids improve muscle function in humans.
Review
Omega-3 polyunsaturated fatty acids improve muscle function in humans (sedentary).
Reviewsedentaryfish oil-derivedskeletal muscle
Time-to-first major cardiovascular event or all-cause death
downin humans1no changein humans1HR 0.71–0.77
1 study
Time-to-first major cardiovascular event or all-cause death
downin humans1no changein humans1HR 0.71–0.77
Omega-3 polyunsaturated fatty acids decrease time-to-first major cardiovascular event or all-cause death in humans (maintenance hemodialysis; fixed-effect high-dose subgroup analysis of PISCES and FISH) (HR 0.71, 95% CI 0.60–0.85).
Reviewmaintenance hemodialysis; fixed-effect high-dose subgroup analysis of PISCES and FISH4 g/day
Omega-3 polyunsaturated fatty acids showed no clear effect on time-to-first major cardiovascular event or all-cause death in humans (maintenance hemodialysis; pooled analysis of three trials) (HR 0.77, 95% CI 0.55–1.09; I2=60%).
Reviewmaintenance hemodialysis; pooled analysis of three trialsn = 1,635
Isometric knee flexion peak torque
downin humans1
1 study
Isometric knee flexion peak torque
downin humans1
Omega-3 polyunsaturated fatty acids impair isometric knee flexion peak torque in combination with leucine-enriched protein (d = −0.43).
Human trialin combination with leucine-enriched protein24-wkn = 107
Omega-3 polyunsaturated fatty acids impair isometric knee flexion peak torque in humans (combined with leucine-enriched protein) (-7.1 Nm; 95% CI: -12.5, -1.8 Nm; P < 0.01).
Human trialcombined with leucine-enriched protein24 wk
FSTL1
no changein humans1upin humans1
1 study
FSTL1
no changein humans1upin humans1
Omega-3 polyunsaturated fatty acids showed no clear effect on FSTL1 in humans (between-group comparison after intervention).
Human trialbetween-group comparison after intervention1,200 mg daily8 weeksmales
Omega-3 polyunsaturated fatty acids increase FSTL1 in humans within-group change in the omega-3 group (+27.6% within omega-3 group).
Human trialwithin-group change in the omega-3 group1,200 mg daily8 weeksmales
Creatine kinase and inflammatory markers
no changein humans1
1 study
Creatine kinase and inflammatory markers
no changein humans1
Omega-3 polyunsaturated fatty acids showed no clear effect on creatine kinase and inflammatory markers in humans after eccentric-emphasized leg extensions; compared with placebo.
Human trialafter eccentric-emphasized leg extensions; compared with placeboalgae oil5 mL oil containing 2 g PUFA8 weeksn = 43
Functional recovery
no changein humans1
1 study
Functional recovery
no changein humans1
Omega-3 polyunsaturated fatty acids showed no clear effect on functional recovery in humans after eccentric-emphasized leg extensions.
Human trialafter eccentric-emphasized leg extensionsalgae oilquadriceps muscle5 mL oil containing 2 g PUFA8 weeksn = 43
Recurrent major cardiovascular events
downin humans1HR 0.57
1 study
Recurrent major cardiovascular events
downin humans1HR 0.57
Omega-3 polyunsaturated fatty acids decrease recurrent major cardiovascular events in humans (maintenance hemodialysis; PISCES trial) (HR 0.57, 95% CI 0.47–0.70; P<0.001).
Reviewmaintenance hemodialysis; PISCES trial4 g/daymedian follow-up 3.5 yearsn = 1,228
Brain entropy
downin humans1
1 study
Brain entropy
downin humans1
Omega-3 polyunsaturated fatty acids decrease brain entropy in humans.
Human trialbrain52-weekn = 20
Blood lipid profiles
upin humans1
1 study
Blood lipid profiles
upin humans1
Omega-3 polyunsaturated fatty acids improve blood lipid profiles in humans (supplemented runners).
Human trialsupplemented runners3,000 mg dailythree weeksmales
Cardiac damage markers
downin humans1
1 study
Cardiac damage markers
downin humans1
Omega-3 polyunsaturated fatty acids decrease cardiac damage markers in humans (compared with placebo group).
Human trialcompared with placebo group3,000 mg dailythree weeksmales
Inflammation mediators
downin humans1
1 study
Inflammation mediators
downin humans1
Omega-3 polyunsaturated fatty acids decrease inflammation mediators in humans (measured after downhill running (eccentric exercise)).
Human trialmeasured after downhill running (eccentric exercise)3,000 mg dailythree weeksmales
Erythrocyte membrane EPA and DHA content
upin humans1
1 study
Erythrocyte membrane EPA and DHA content
upin humans1
Omega-3 polyunsaturated fatty acids increase erythrocyte membrane EPA and DHA content in humans (3 weeks of supplementation compared with baseline).
Human trial3 weeks of supplementation compared with baselineerythrocyte3,000 mg dailythree weeksmales
All 63Fewer
What is omega-3 polyunsaturated fatty acids linked with?
14Studies link omega-3 polyunsaturated fatty acids with 14 measures, among them Alzheimer's disease, cognitive function and lipid profile parameters.
Alzheimer's disease
downin humans1downin reviews1
2 studies
Alzheimer's disease
downin humans1downin reviews1
Omega-3 polyunsaturated fatty acids are associated with Alzheimer's disease in humans.
Reviewhigher levels
Omega-3 polyunsaturated fatty acids lower the risk of Alzheimer's disease.
Review
Cognitive function
no changein humans1upin humans1
2 studies
Cognitive function
no changein humans1upin humans1
Omega-3 polyunsaturated fatty acids are associated with cognitive function in humans (minor alleles at 22 identified SNPs).
Humansminor alleles at 22 identified SNPserythrocyten = 1,620
Omega-3 polyunsaturated fatty acids are associated with cognitive function in humans.
Reviewhigher levels
Lipid profile parameters
mixedin humans1
1 study
Lipid profile parameters
mixedin humans1
Omega-3 polyunsaturated fatty acids are associated with lipid profile parameters in humans (patients with cardiovascular diseases).
Human trialpatients with cardiovascular diseasesdietary therapy enriched with various sources300 to 3000 mg per day
Lung cancer
downin humans1OR 0.82
1 study
Lung cancer
downin humans1OR 0.82
Omega-3 polyunsaturated fatty acids are linked with a lower risk of lung cancer in humans (OR 0.82, 95% CI 0.70-0.96).
Humans1 g/day
Cardiovascular health
upin humans1
1 study
Cardiovascular health
upin humans1
Omega-3 polyunsaturated fatty acids are associated with cardiovascular health in humans.
Reviewhigher levels
Temporal lobe volume
downin humans1
1 study
Temporal lobe volume
downin humans1
Omega-3 polyunsaturated fatty acids are associated with temporal lobe volume in humans (Alzheimer's disease) (β = - 0.31, p = 0.021).
HumansAlzheimer's diseasetemporal lobe
Depression
downin humans1
1 study
Depression
downin humans1
Omega-3 polyunsaturated fatty acids are associated with depression in humans.
Review
Allostatic load-related disease risk
downin humans1
1 study
Allostatic load-related disease risk
downin humans1
Omega-3 polyunsaturated fatty acids are associated with allostatic load-related disease risk in humans.
HumansHigher intake
Bone health
mixedin humans1
1 study
Bone health
mixedin humans1
Omega-3 polyunsaturated fatty acids are associated with bone health in humans.
Review
Biological-age acceleration
downin humans1
1 study
Biological-age acceleration
downin humans1
Omega-3 polyunsaturated fatty acids are associated with biological-age acceleration in humans (β -0.18, 95% CI -0.27, -0.08, P < 0.05).
Humansn = 26,381
All 14Fewer
Has omega-3 polyunsaturated fatty acids been tested in people?
10 of 21 about agingYes: 11 trials and 14 observational studies in people have been published.
About aging
A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline
Completed
Omega-3 Fatty Acids and Muscle Protein Synthesis
Completed
Vitamin D and Omega-3 Trial (VITAL)
Phase 3Active, not recruiting
VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers
Completed
Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)
Status unknown
ASCEND: A Study of Cardiovascular Events iN Diabetes
Phase 4Active, not recruiting
All 10Fewer
Funding
1 grant since 2016Japan Society for the Promotion of Science¥3M
How this record changed
Summary written from the findings.